Bavarian Nordic abandons Covid booster after data show it's not as effective against new variants
01 Sep 2023
VaccinePhase 3
Bavarian Nordic is abandoning its Covid-19 booster vaccine after Phase III results — even though it did hit the primary endpoint of the study — because it’s not as effective against newer variants of the virus.
The capsid virus-like particle (cVLP) based booster, called ABNCoV2, did lower the levels of neutralizing antibodies against the original SARS-CoV-2 variant. But even if the data found that it was non-inferior to the participants in the study who were vaccinated with Pfizer and BioNTech’s Comirnaty, it was for a variant that is “no longer the primary concern,” Bavarian said.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.